Histone deacetylase inhibitors (HDACis) such as romidepsin and panobinostat enhance histone acetylation, promoting senescence in BC and OC by upregulating p21 and suppressing cyclin-dependent kinases, while also modulating the SASP to remodel the tumor microenvironment [349, 350]. Here, CDKN1A is linked to neoplasm.